Current Report Filing (8-k)
March 28 2017 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2017
OREXIGEN THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-33415
|
|
65-1178822
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
3344 N. Torrey Pines Court, Suite 200,
La Jolla, CA
|
|
92037
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(858) 875-8600
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4I
under the Exchange Act (17 CFR
240.13e-4I)
|
Item 2.02
|
Results of Operations and Financial Condition
|
On March 28, 2017, Orexigen
Therapeutics, Inc. (
Orexigen
or the
Company
) issued a press release announcing its financial results for the three months and year ended December 31, 2016. A copy of this press release is
attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form
8-K,
the
information in this Current Report on Form
8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act
), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or
after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form
8-K.
Item 9.01
|
Financial Statements and Exhibits
|
(d)
Exhibits
.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated March 28, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
OREXIGEN THERAPEUTICS, INC.
|
|
|
|
|
Date: March 28, 2017
|
|
|
|
By:
|
|
/s/ Michael A. Narachi
|
|
|
|
|
Name:
|
|
Michael A. Narachi
|
|
|
|
|
Title:
|
|
Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated March 28, 2017
|